Literature DB >> 20873097

[Molecular control of bone resorption in chronic otitis media with cholesteatoma].

Jerzy Kuczkowski1, Grazyna Kobierska-Gulida, Ewa Izycka-Swieszewska, Małgorzata Potocka, Bogusław Mikaszewski, Wojciech Sierszeń.   

Abstract

UNLABELLED: Bone destruction in chronic otitis media with cholesteatoma is a common phenomenon. Expanding growth of cholesteatoma in the middle ear causes ischemia of the mucosa and bones with granulation tissue production. THE AIM OF THIS STUDY: was to assess the expression and distribution of the key regulators of bone destruction: osteoprotegerin (OPG), Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) and tumour necrosis factor alpha (TNF-alpha) in chronic otitis media with cholesteatoma and their role in the pathomechanism of bone resorption.
MATERIAL AND METHODS: We performed immunohistochemical study of the cholesteatoma tissue collected from 21 patients suffering from chronic otitis media with cholesteatoma and 16 samples of normal external auditory meatal skin. This material was analysed histopathologically and by means of immunoperoxidase immunohistochemical technique with the use of antibodies against OPG, RANKL and TNF-alpha and their quantitive evaluation.
RESULTS: In all patients with cholesteatoma, features of auditory ossicles and temporal bone destruction were demonstrated. We found that cholesteatoma and granulation tissue cells release factors of the OPG/ RANKL/RANK system and TNF-alpha. In cholestatoma a higher expression of RANKL, OPG and TNF-alpha positive was demonstrated when comparing to the skin of external auditory meatus. These factors were relatively higher expressed in the stroma rather than in the epithelium of cholesteatoma. RANKL-positive cells were demonstrated mainly in the stroma cells, whereas OPG-positive ones in the cholesteatoma epithelium. The reaction with the antibodies against OPG, RANKL and TNF-alpha was weak in the external auditory meatal skin.
CONCLUSIONS: Bone destruction in chronic otitis media with cholesteatoma is a common process dependent on osteoclast activating factors. OPG/ RANKL/RANK system and TNF-alpha play a key role in the process of osteolysis in otitis media with cholesteatoma. We found no positive correlation between bone destruction advancement and the level of examinated proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20873097     DOI: 10.1016/S0030-6657(10)70019-6

Source DB:  PubMed          Journal:  Otolaryngol Pol        ISSN: 0030-6657


  6 in total

Review 1.  The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma.

Authors:  Shumin Xie; Xiaoli Wang; Jihao Ren; Wei Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-16       Impact factor: 2.503

2.  Osteoclasts Modulate Bone Erosion in Cholesteatoma via RANKL Signaling.

Authors:  Ryusuke Imai; Takashi Sato; Yoriko Iwamoto; Yukiko Hanada; Mika Terao; Yumi Ohta; Yasuhiro Osaki; Takao Imai; Tetsuo Morihana; Suzuyo Okazaki; Kazuo Oshima; Daisuke Okuzaki; Ichiro Katayama; Hidenori Inohara
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-28

3.  Can we avoid intracranial complications of chronic otitis media?

Authors:  Jerzy Kuczkowski; Dmitry Tretiakow; Wojciech Brzoznowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-04       Impact factor: 2.503

4.  Why does the acquired cholesteatoma trigger resorption of the temporal bone?

Authors:  Jerzy Kuczkowski; Tomasz K Nowicki; Anna Starzyńska
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-14       Impact factor: 2.503

5.  Pattern of cholesteatomas under a scanning electron microscope - a risk factor for bone resorption.

Authors:  Agnieszka Wiatr; Katarzyna Job; Maciej Wiatr
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-08       Impact factor: 2.124

Review 6.  Review of potential medical treatments for middle ear cholesteatoma.

Authors:  Matthias Schürmann; Peter Goon; Holger Sudhoff
Journal:  Cell Commun Signal       Date:  2022-09-19       Impact factor: 7.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.